Impact Factor
4.86
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
11.64
9,569 total citations
h5-index
121
h5 depth signal
Cited share
86.4%
742 of 859
Total citations
9,569
Citation footprint
Metric signal
10.05
External metric anchor
Self-citation
2.2%
213 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,860
United Kingdom
1,300
Germany
769
France
517
Italy
459
Citing Fields of Research
Neurodegenerative Disorders
1,976
Neurosciences
1,000
Brain Neurological Disorders
736
Neuromuscular Disorders
496
Nervous System Disorders
387
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
19,173
Articles tracked across the journal lifetime
Indexed publication set
859
742 cited publications
Last 12 months
448
37.3 publications/month
Open access share
46.9%
210 OA publications in the last year
Leading citing country
United States
1,860 citing publications
Leading citing field
Neurodegenerative Disorders
1,976 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v88n2,Jun. 1965-
v88n2,Jun. 1965-
Active Coverage
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Neurosciences
Neuromuscular Disorders
Brain Neurological Disorders
Broad Categories
Brain
Neurology
Neurodegenerative Disorders
Neurosciences
Neuromuscular Disorders
Brain Neurological Disorders
Musculoskeletal Disorders
MeSH Descriptors
Neurology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/brain/awag360
Open DOI
A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis
This scientific commentary refers to ‘Multimodal discovery of a pathogenic B cell-dependent T cell state in multiple sclerosis’ by Farooq et al. (https://doi.org/10.1093/brain/awag303).
02
DOI 10.1093/brain/awag330
Open DOI
Is the entorhinal signal a tau origin or a treatment-relevant vulnerability map?
03
DOI 10.1093/brain/awag359
Open DOI
Neuronavigated dual-target transcranial magnetic stimulation for schizophrenia negative symptoms
Negative symptoms in schizophrenia severely impair function and quality of life, yet respond poorly to current therapies. This multicenter, randomized, double-blind, sham-controlled trial aimed to investigate the efficacy of neuronavigat...
04
DOI 10.1093/brain/awag355
Open DOI
Biallelic variants in PIKFYVE cause a hypomyelinating leukodystrophy with endolysosomal dysfunction
The PIKfyve-FIG4-VAC14 lipid kinase complex generates phosphoinositide PI(3,5)P2. Pathogenic variants in VAC14 and FIG4 cause neurodevelopmental disorders and PIKFYVE has been linked to autosomal dominant fleck corneal dystrophy. We sear...
05
DOI 10.1093/brain/awag356
Open DOI
Extracellular vesicle α-synuclein topology reveals disease-associated conformers in brain and blood
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are unified by pathological α-synuclein (αSyn) aggregation, yet diverge in terms of the cellular distribution of pathology and clinical phenotyp...
06
DOI 10.1093/brain/awag353
Open DOI
Target engagement and efficacy in disease-modifying trials of synuclein-related disorders
Disease-modifying trials in Parkinson’s disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) increasingly incorporate fluid and imaging biomarkers to demonstrate target engagement, de-risk subsequent phases of...
07
DOI 10.1093/brain/awag354
Open DOI
Mapping therapeutic neural circuits from bed nucleus of stria terminalis biomarkers
08
DOI 10.1093/brain/awag346
Open DOI
Progress divides the room: patients, biology and the 2024 McDonald criteria
09
DOI 10.1093/brain/awag350
Open DOI
The genetic landscape of myotonic dystrophy type 1: insights from nearly one million genomes
Myotonic Dystrophy type 1 (DM1) is a multisystem disorder caused by CTG repeat expansions in the dystrophia myotonica protein kinase (DMPK) gene. Current prevalence estimates of 1 in 3,000-8,000 have traditionally relied on clinically as...
10
DOI 10.1093/brain/awag347
Open DOI
White matter hyperintensity burden in amyotrophic lateral sclerosis: motor and survival correlates
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. Microvascular dysfunction has been implicated by recent research in ALS pathogenesis and motor neuron vulne...
Bibliographical & Catalog Notes
Available also online.
Microfilm. v.1(1878)-75(1952),94(1971). 33 microfilm reels : negative ; 35 mm.
Indexes: Vols. 1-23, 1878-1900. 1 v.
Complemented by (work): Brain communications 2632-1297 (OCoLC)1096460459 (DLC) 2020243186 (DNLM)101755125.
Vol. 105, PT 1 (MAR 1982)19920831 Notice not published Printed on acid-free paper